Columbia University Clinical Trial: Gepirone in the Treatment of Atypical Depression.

Gepirone is of one a new class of antidepressants, being tested for the treatment of atypical depression. A previous study at Columbia University suggested that gepirone may be effective in treating people with atypical depression. Further, in that study, the medication appeared not to be associated with the weight gain and sexual side effects seen with many antidepressants.

Gepirone is an investigational medication still under study and has not been FDA approved in the United States.

The study randomly assigns participants with Major Depression and atypical features to treatment with gepirone, fluoxetine (Prozac), or placebo for 8 weeks. Responders to the treatment can continue on that treatment in an extension phase of the study for up to one year. Those who do not respond to the initial treatment, or who find side effects of that treatment intolerable, may switch to another of the study treatments. All evaluation and treatment is completely confidential and evening appointments are available after initial evaluation.

All study treatment and medication is provided at no cost through the study.

For further information or to participate, contact:

Vito Agosti, CSW
Phone = 212-543-5734
Email = agostiv@pi.cpmc.columbia.edu

Return to Depression Central

Revised VII/28/01